Renovaro Biosciences Inc (RENB) - Net Assets
Based on the latest financial reports, Renovaro Biosciences Inc (RENB) has net assets worth $-21.35 Million USD as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($8.23 Million) and total liabilities ($29.58 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of Renovaro Biosciences Inc to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-21.35 Million |
| % of Total Assets | -259.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | -24.44% |
| 10-Year Change | N/A |
| Growth Volatility | 3224.95 |
Renovaro Biosciences Inc - Net Assets Trend (2012–2025)
This chart illustrates how Renovaro Biosciences Inc's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Renovaro Biosciences Inc for the complete picture of this company's asset base.
Annual Net Assets for Renovaro Biosciences Inc (2012–2025)
The table below shows the annual net assets of Renovaro Biosciences Inc from 2012 to 2025. For live valuation and market cap data, see RENB market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $131.98 Million | 0.00% |
| 2024-06-30 | $131.98 Million | +183.81% |
| 2023-06-30 | $46.50 Million | -35.96% |
| 2022-06-30 | $72.62 Million | -58.42% |
| 2021-06-30 | $174.66 Million | +5.05% |
| 2020-06-30 | $166.27 Million | -3.94% |
| 2019-06-30 | $173.10 Million | +9.05% |
| 2018-06-30 | $158.74 Million | +10256.51% |
| 2017-06-30 | $1.53 Million | +340.47% |
| 2016-06-30 | $-637.40K | -118.30% |
| 2015-06-30 | $3.48 Million | +317.64% |
| 2014-06-30 | $-1.60 Million | -3020.79% |
| 2013-06-30 | $-51.27K | -274.77% |
| 2012-06-30 | $-13.68K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Renovaro Biosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 33244634600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $15.50K | 0.01% |
| Other Comprehensive Income | $-170.85K | -0.13% |
| Other Components | $464.59 Million | 352.02% |
| Total Equity | $131.98 Million | 100.00% |
Renovaro Biosciences Inc Competitors by Market Cap
The table below lists competitors of Renovaro Biosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Legacy Minerals Holdings Ltd
AU:LGM
|
$26.19 Million |
|
Champion Pacific Indonesia Tbk
JK:IGAR
|
$26.20 Million |
|
Hansol Pns
KO:010420
|
$26.22 Million |
|
Thai Film Industries Public Company Limited
BK:TFI
|
$26.22 Million |
|
Hanwha Investment&Securities Co Ltd Pref
KO:003535
|
$26.19 Million |
|
Thai O.P.P. Public Company Limited
BK:TOPP
|
$26.18 Million |
|
Global Surfaces Limited
NSE:GSLSU
|
$26.18 Million |
|
Andromeda Metals Ltd
AU:ADN
|
$26.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Renovaro Biosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 131,977,144 to 131,977,144, a change of 0 (0.0%).
- Net loss of 80,650,172 reduced equity.
- New share issuances of 2,376,181 increased equity.
- Other factors increased equity by 78,273,991.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-80.65 Million | -61.11% |
| Share Issuances | $2.38 Million | +1.8% |
| Other Changes | $78.27 Million | +59.31% |
| Total Change | $- | 0.00% |
Book Value vs Market Value Analysis
This analysis compares Renovaro Biosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.08x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-06-30 | $-0.01 | $1.13 | x |
| 2013-06-30 | $-0.05 | $1.13 | x |
| 2015-06-30 | $4.64 | $1.13 | x |
| 2016-06-30 | $-0.67 | $1.13 | x |
| 2017-06-30 | $1.25 | $1.13 | x |
| 2018-06-30 | $72.35 | $1.13 | x |
| 2019-06-30 | $46.10 | $1.13 | x |
| 2020-06-30 | $35.89 | $1.13 | x |
| 2021-06-30 | $37.03 | $1.13 | x |
| 2022-06-30 | $13.82 | $1.13 | x |
| 2023-06-30 | $8.26 | $1.13 | x |
| 2024-06-30 | $1.37 | $1.13 | x |
| 2025-06-30 | $13.71 | $1.13 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Renovaro Biosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -61.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.24x
- Recent ROE (-61.11%) is below the historical average (-46.78%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.58K |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-32.46K |
| 2015 | -68.08% | 0.00% | 0.00x | 1.50x | $-2.72 Million |
| 2016 | 0.00% | -4057.24% | 0.05x | 0.00x | $-1.67 Million |
| 2017 | -139.80% | 0.00% | 0.00x | 2.95x | $-2.30 Million |
| 2018 | -3.98% | 0.00% | 0.00x | 1.15x | $-22.19 Million |
| 2019 | -10.41% | 0.00% | 0.00x | 1.04x | $-35.33 Million |
| 2020 | -6.87% | 0.00% | 0.00x | 1.07x | $-28.04 Million |
| 2021 | -15.30% | 0.00% | 0.00x | 1.09x | $-44.19 Million |
| 2022 | -156.20% | 0.00% | 0.00x | 1.17x | $-120.70 Million |
| 2023 | -85.34% | 0.00% | 0.00x | 1.25x | $-44.33 Million |
| 2024 | -61.11% | 0.00% | 0.00x | 1.24x | $-93.85 Million |
| 2025 | -61.11% | 0.00% | 0.00x | 1.24x | $-93.85 Million |
Industry Comparison
This section compares Renovaro Biosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Renovaro Biosciences Inc (RENB) | $-21.35 Million | 0.00% | N/A | $26.19 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About Renovaro Biosciences Inc
Lunai Bioworks Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands. It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors… Read more